FLT1 and neoplasm: Although initial phase 1 trials with anti-VEGFR-1 IMC-18F1 (Icrucumab) showed some potential anti-tumor activity [28], combination with the chemotherapy Capecitabine in patients with advanced or metastatic breast cancer did not significantly improve the response compared to chemotherapy alone [29].